Skip to content
Homepage
Author:
Servier Pharmaceuticals
Posted Date:
June 26, 2026
Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio
Servier Pharmaceuticals
June 26, 2026
Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
Servier Pharmaceuticals
June 25, 2026
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
Servier Pharmaceuticals
June 1, 2026
Promising Phase 1 Data for Servier’s Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
Servier Pharmaceuticals
June 1, 2026
